milrinone and Sensitivity and Specificity studies

Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)

Research Excerpts

Excerpt	Relevance	Reference
"Pretreatment with milrinone markedly enhanced relaxation to prostacyclin and iloprost in PPHN PA, similar to relaxation in control PA."	5.35	Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. ( Chen, B; Farrow, KN; Gugino, SF; Kumar, VH; Lakshminrusimha, S; Porta, NF; Russell, JA; Steinhorn, RH, 2009)
"Milrinone administered through inhalation is an emerging method aimed at specifically reducing pulmonary hypertension without affecting systemic pressures."	3.80	A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. ( Denault, AY; Gavra, P; Litalien, C; Nguyen, AQ; Theoret, Y; Varin, F, 2014)
"Milrinone was separated on a strong cation exchange analytical column."	1.40	High-performance liquid chromatography assay using ultraviolet detection for urinary quantification of milrinone concentrations in cardiac surgery patients undergoing cardiopulmonary bypass. ( Beauregard, N; Denault, AY; Gavra, P; Nguyen, AQ; Varin, F, 2014)
"Milrinone is a bipyridine phosphodiesterase inhibitor with positive inotropic and vasodilatory effects."	1.38	A clinical assay for the measurement of milrinone in plasma by HPLC mass spectrometry. ( Banner, NR; Chihoho, B; Leaver, NV; Rose, ML; Sage, AB; Smolenski, RT; Vazir, A, 2012)
"Pretreatment with milrinone markedly enhanced relaxation to prostacyclin and iloprost in PPHN PA, similar to relaxation in control PA."	1.35	Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. ( Chen, B; Farrow, KN; Gugino, SF; Kumar, VH; Lakshminrusimha, S; Porta, NF; Russell, JA; Steinhorn, RH, 2009)
"Milrinone was separated on a strong cation exchange analytical column maintained at 23."	1.35	High performance liquid chromatography using UV detection for the quantification of milrinone in plasma: improved sensitivity for inhalation. ( Chen, C; Denault, A; Nguyen, AQ; Théorêt, Y; Varin, F, 2009)
"Pretreatment with milrinone and nitroprusside significantly inhibited vasopressin contraction in the internal thoracic artery but had little effect in the radial artery."	1.33	Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery. ( Furnary, A; He, GW; Wei, W; Yang, CQ, 2005)
" The utility of the assay was demonstrated in a pharmacokinetic evaluation of milrinone in two rats given intravenous bolus doses."	1.33	A sensitive and specific high performance liquid chromatographic assay for milrinone in rat and human plasma using a commercially available internal standard and low sample volume. ( Brocks, DR; Shayeganpour, A; Spencer, TJ, 2005)

Research

Studies (12)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (8.33)	18.2507
2000's	8 (66.67)	29.6817
2010's	3 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Diamandis, P	1
Wildenhain, J	1
Clarke, ID	1
Sacher, AG	1
Graham, J	1
Bellows, DS	1
Ling, EK	1
Ward, RJ	1
Jamieson, LG	1
Tyers, M	1
Dirks, PB	1
Gavra, P	2
Nguyen, AQ	3
Beauregard, N	1
Denault, AY	2
Varin, F	3
Theoret, Y	2
Litalien, C	1
Lakshminrusimha, S	1
Porta, NF	1
Farrow, KN	1
Chen, B	1
Gugino, SF	1
Kumar, VH	1
Russell, JA	1
Steinhorn, RH	1
Chen, C	1
Denault, A	1
Chihoho, B	1
Sage, AB	1
Smolenski, RT	1
Vazir, A	1
Rose, ML	1
Banner, NR	1
Leaver, NV	1
Matot, I	1
Gozal, Y	1
Wei, W	1
Yang, CQ	1
Furnary, A	1
He, GW	1
Brocks, DR	1
Spencer, TJ	1
Shayeganpour, A	1
El-Kemary, M	1
Organero, JA	1
Santos, L	1
Douhal, A	1
Ritchie, RH	1
Hii, JT	1
Horowitz, JD	1
Thomas, RE	1
Armstrong, DT	1
Gilchrist, RB	1

Trial	Enrollment	Study Type	Start Date	Status
Serum Levels of C Type Natriuretic Peptide in Reproductive Age, Perimenopausal and Postmenopausal Women[NCT04000815]	71 participants (Actual)	Interventional	2019-07-24	Completed
C Type Natriuretic Peptide and Polycystic Ovary Syndrome[NCT04006171]	90 participants (Actual)	Interventional	2019-07-15	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Correlation between serum CNP and antral follicle count (AFC) in groups 1 and 2 using Spearman test (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2

Intervention	follicles (Mean)
Reproductive Age Women	14.2
Perimenopausal Women	8.33

Correlation of CNP vs. Estradiol levels in reproductive age and perimenopausal women (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Serum C Type Natriuretic Peptide Levels

Intervention	pg/mL (Median)
Reproductive Age Women	41
Perimenopausal Women	22

The comparison of serum levels of C type natriuretic peptide among different age groups (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2

Intervention	pg/ml (Median)
Reproductive Age Women	43.68
Perimenopausal Women	55.98
Postmenopausal Women	116.36

Correlations between serum CNP vs Follicle Stimulating Hormone(FSH), CNP vs Luteinizing Hormone(LH) levels in groups 1 and 2 (NCT04000815)
Timeframe: Second or Third Day of Menstruation

Free Androgen Index of Participants

Intervention	mIU/mL (Median)
	Follicle Stimulating Hormone	Luteinizing Hormone
Perimenopausal Women	13.12	5.16
Reproductive Age Women	5.28	5.71

Free androgen index of participants were compared. It was calculated with the formula 100XTotal testosterone/Sex hormone binding globulin (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Homeostatic Model Assessment of Insulin Resistance of Participants

Intervention	% of T testosterone per SHBG (Mean)
Women With Polycystic Ovary Syndrome	4.39
Healthy Women of Reproductive Age	1.55

homeostatic model assessment of insulin resistance of participants were compared. The calculation was made with formula Glucose X Insulin/405. (NCT04006171)
Timeframe: Second or Third Day of Menstruation-morning fasting

Roc Curve of CNP

Intervention	HOMA-IR Index (Median)
Women With Polycystic Ovary Syndrome	1.50
Healthy Women of Reproductive Age	1.45

We made a cut off value estimation for the diagnosis of PCOS by serum CNP levels using Receiver operator characteristics. The ROC curve incorporates both sensitivity (true positive rate) and specificity (true negative rate) providing a single assessment incorporating both measures. The higher the total area under the curve, the greater the predictive power of the CNP for diagnosing PCOS (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Androstenedione Levels of PCOS and Healthy Women

Intervention	probability (Number)
All Participants	0.706

Serum Androstenedione Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum CNP Levels of PCOS and Healthy Participants

Intervention	ng/dL (Mean)
Women With Polycystic Ovary Syndrome	148.89
Healthy Women of Reproductive Age	84.66

The comparison of serum levels of C type natriuretic peptide among PCOS and healthy women (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Dehydroepiandrosterone Sulfate (DHEAS) Levels of PCOS and Healthy Women

Intervention	pg/ml (Median)
Women With Polycystic Ovary Syndrome	110
Healthy Women of Reproductive Age	57

Serum dehydroepiandrosterone sulfate (DHEAS) Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Estradiol Levels of PCOS and Healthy Women

Intervention	µg/dL (Median)
Women With Polycystic Ovary Syndrome	304.55
Healthy Women of Reproductive Age	299.95

Serum Estradiol levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Free Testosterone Levels of PCOS and Healthy Women

Intervention	pg/mL (Median)
Women With Polycystic Ovary Syndrome	31
Healthy Women of Reproductive Age	36.5

Serum Free Testosterone Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Insulin Levels of Participants

Intervention	pg/mL (Mean)
Women With Polycystic Ovary Syndrome	1.71
Healthy Women of Reproductive Age	1.12

Serum Insulin Levels of Participants were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation-morning fasting

Serum Prolactin Levels of PCOS and Healthy Women

Intervention	mU/L (Median)
Women With Polycystic Ovary Syndrome	7.10
Healthy Women of Reproductive Age	7.10

serum prolactin levels of PCOS and healthy women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women

Intervention	ng/mL (Mean)
Women With Polycystic Ovary Syndrome	17.21
Healthy Women of Reproductive Age	16.80

Serum Sex Hormone Binding Globulin Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Tiroid Stimulating Hormone of PCOS and Healthy Women

Intervention	nmol/L (Median)
Women With Polycystic Ovary Syndrome	30.4
Healthy Women of Reproductive Age	59.4

serum tiroid stimulating hormone of PCOS and healthy women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Serum Total Testosterone Levels of PCOS and Healthy Women

Intervention	mIU/L (Median)
Women With Polycystic Ovary Syndrome	1.61
Healthy Women of Reproductive Age	1.47

Serum Total Testosterone Levels of PCOS and Healthy Women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

Comparison of FSH and LH of PCOS and Healthy Women

Intervention	nmol/L (Mean)
Women With Polycystic Ovary Syndrome	1.38
Healthy Women of Reproductive Age	0.92

Serum FSH and LH of PCOS and healthy women were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation

High Density Lipoprotein and Low Density Lipoprotein Levels of Participants

Intervention	mIU/mL (Median)
	Follicle Stimulating Hormone	Luteinizing Hormone
Healthy Women of Reproductive Age	4.97	5.36
Women With Polycystic Ovary Syndrome	4.7	4.23

High density lipoprotein and low density lipoprotein levels of participants were compared (NCT04006171)
Timeframe: Second or Third Day of Menstruation-morning fasting

Serum Glucose, Total Cholesterol and Triglycerides Levels of Participants

Intervention	mg/dL (Mean)
	High density lipoprotein	Low density lipoprotein
Healthy Women of Reproductive Age	62.15	92.92
Women With Polycystic Ovary Syndrome	53.82	98.50

Serum glucose, total cholesterol and triglycerides levels of participants were compared (NCT04006171)
Timeframe: Second or third day of menstruation and morning fasting

Article	Year
Chemical genetics reveals a complex functional ground state of neural stem cells. Nature chemical biology, 2007, Volume: 3, Issue:5 Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic	2007
High-performance liquid chromatography assay using ultraviolet detection for urinary quantification of milrinone concentrations in cardiac surgery patients undergoing cardiopulmonary bypass. Biomedical chromatography : BMC, 2014, Volume: 28, Issue:8 Topics: Administration, Inhalation; Cardiopulmonary Bypass; Cardiotonic Agents; Chromatography, High Pressur	2014
A specific and sensitive HPLC-MS/MS micromethod for milrinone plasma levels determination after inhalation in cardiac patients. Therapeutic drug monitoring, 2014, Volume: 36, Issue:5 Topics: Administration, Inhalation; Cardiopulmonary Bypass; Chemical Fractionation; Chromatography, High Pre	2014
Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 2009, Volume: 10, Issue:1 Topics: Animals; Animals, Newborn; Blotting, Western; Disease Models, Animal; Drug Interactions; Drug Therap	2009
High performance liquid chromatography using UV detection for the quantification of milrinone in plasma: improved sensitivity for inhalation. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Mar-01, Volume: 877, Issue:7 Topics: Administration, Inhalation; Chromatography, High Pressure Liquid; Milrinone; Sensitivity and Specifi	2009
A clinical assay for the measurement of milrinone in plasma by HPLC mass spectrometry. Biomedical chromatography : BMC, 2012, Volume: 26, Issue:5 Topics: Chromatography, High Pressure Liquid; Drug Monitoring; Drug Stability; Heart Failure; Humans; Linear	2012
Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest, 2004, Volume: 125, Issue:2 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; 3',5'-Cyclic-AMP Phosphodiestera	2004
Greater vasopressin-induced vasoconstriction and inferior effects of nitrovasodilators and milrinone in the radial artery than in the internal thoracic artery. The Journal of thoracic and cardiovascular surgery, 2005, Volume: 129, Issue:1 Topics: Analysis of Variance; Coronary Artery Bypass; Drug Interactions; Female; Humans; Male; Mammary Arter	2005
A sensitive and specific high performance liquid chromatographic assay for milrinone in rat and human plasma using a commercially available internal standard and low sample volume. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2005, Jun-24, Volume: 8, Issue:2 Topics: Animals; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Humans; Milrinone; Rats; R	2005
Effect of cyclodextrin nanocavity confinement on the photorelaxation of the cardiotonic drug milrinone. The journal of physical chemistry. B, 2006, Jul-27, Volume: 110, Issue:29 Topics: Cardiotonic Agents; Cyclodextrins; Milrinone; Models, Molecular; Molecular Structure; Nanostructures	2006
Relationship between myocardial milrinone content and its acute hemodynamic and electrophysiologic effects. Journal of cardiovascular pharmacology, 1998, Volume: 31, Issue:6 Topics: Adult; Aged; Chromatography, High Pressure Liquid; Hemodynamics; Humans; Male; Middle Aged; Milrinon	1998
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002
Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Developmental biology, 2002, Apr-15, Volume: 244, Issue:2 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cattle; Cell Culture Techniques; Cells, Cultured; Cycl	2002

Intervention	mg/dL (Median)
	Total cholesterol	triglycerides	Glucose
Healthy Women of Reproductive Age	171	77	89
Women With Polycystic Ovary Syndrome	164	78	88.5

milrinone and Sensitivity and Specificity